We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD) (InPedILD®)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04093024
Recruitment Status : Completed
First Posted : September 17, 2019
Last Update Posted : June 22, 2022
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).

Condition or disease Intervention/treatment Phase
Lung Diseases, Interstitial Drug: Nintedanib (Ofev®) Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents (6 to 17 Year-old) With Clinically Significant Fibrosing Interstitial Lung Disease
Actual Study Start Date : December 3, 2019
Actual Primary Completion Date : May 24, 2022
Actual Study Completion Date : May 24, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Nintedanib (Ofev®) Drug: Nintedanib (Ofev®)

Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Area under the Plasma Concentration-Time Curve at Steady State (AUCτ,ss) based on sampling at steady state (at week 2 and week 26); [ Time Frame: Week 2 and Week 26 ]
  2. N (%) of patients with treatment-emergent adverse events at week 24 [ Time Frame: Week 24 ]

Secondary Outcome Measures :
  1. N (%) of patients with treatment-emergent pathological findings of epiphyseal growth plate on imaging at week 24, and week 52 [ Time Frame: Week 24 and Week 52 ]
  2. N (%) of patients with treatment-emergent pathological findings on dental examination or imaging at week 24, and week 52 [ Time Frame: Week 24 and Week 52 ]
  3. N (%) of patients with treatment-emergent adverse events over the whole trial [ Time Frame: Up to 29 months ]
  4. Change in height from baseline at week 24, week 52, week 76, and week 100 [ Time Frame: Baseline, Week 24, Week 52, weeky 76, and week 100 ]
  5. Change in Forced Vital Capacity (FVC) % predicted from baseline at week 24, and week 52 [ Time Frame: Baseline, Week 24 and Week 52 ]
  6. Absolute change from baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at week 24, and week 52 [ Time Frame: Baseline, Week 24 and Week 52 ]
  7. Change in oxygen saturation (SpO2) on room air at rest from baseline at week 24, and week 52 [ Time Frame: Baseline, Week 24 and Week 52 ]
  8. Change in 6-min walk distance from baseline at week 24, and week 52 [ Time Frame: Baseline, Week 24 and Week 52 ]
  9. Patient acceptability based on the size of capsules at week 24 [ Time Frame: Week 24 ]
  10. Patient acceptability based on the number of capsules at week 24 [ Time Frame: Week 24 ]
  11. Time to first respiratory-related hospitalization over the whole trial [ Time Frame: Up to 29 months ]
  12. Time to first acute Interstitial Lung Disease (ILD) exacerbation or death over the whole trial [ Time Frame: Up to 29 months ]
  13. Time to death over the whole trial [ Time Frame: Up to 29 months ]
  14. Change in sitting height from baseline at week 24, week 52, week 76, and week 100 [ Time Frame: Baseline, Week 24, Week 52, Week 76, and Week 100 ]
  15. Change in leg length from baseline at week 24, week 52, week 76, and week 100 [ Time Frame: Baseline, Week 24, Week 52, Week 76, and Week 100 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children and adolescents 6 to 17 years old at Visit 2.
  • Signed and dated written informed consent and assent, where applicable, in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
  • Male or female patients. Female of childbearing potential (WOCBP) must confirm that sexual abstinence is standard practice and will be continued until 3 months after last drug intake, or be ready and able to use a highly effective method of birth control per International Conference on Harmonisation (ICH) M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly, in combination with one barrier method, from 28 days prior to initiation of study treatment, during treatment and until 3 months after last drug intake. Sexual abstinence is defined as abstinence from any sexual act that may result in pregnancy. A list of contraception methods meeting these criteria is provided in the parental information.
  • Patients with evidence of fibrosing Interstitial Lung Disease (ILD) on High-Resolution Computed Tomography (HRCT) within 12 months of Visit 1 as assessed by the investigator and confirmed by central review.
  • Patients with Forced Vital Capacity (FVC)% predicted ≥25% at Visit 2. [Note: Predicted normal values will be calculated according to GLI (Global Lung Initiative)]
  • Patients with clinically significant disease at Visit 2, as assessed by the investigator based on any of the following:

    • Fan score ≥3, or
    • Documented evidence of clinical progression over time based on either

      • a 5-10% relative decline in FVC% predicted accompanied by worsening symptoms, or
      • a ≥10% relative decline in FVC % predicted, or
      • increased fibrosis on HRCT, or
      • other measures of clinical worsening attributed to progressive lung disease (e.g. increased oxygen requirement, decreased diffusion capacity).

Exclusion Criteria:

  • Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT)>1.5 x Upper Level of Normal (ULN) at Visit 1.
  • Bilirubin >1.5 x ULN at Visit 1.
  • Creatinine clearance <30 mL/min calculated by Schwartz formula at Visit 1. [Note: Laboratory parameters from Visit 1 have to satisfy the laboratory threshold values as shown above. Visit 2 laboratory results will be available only after randomization. In case at Visit 2 the results do no longer satisfy the entry criteria, the Investigator has to decide whether it is justified that the patient remains on study drug. The justification for decision needs to be documented. Laboratory parameters that are found to be abnormal at Visit 1 are allowed to be re-tested (once) if it is thought to be a measurement error (i.e. there was no abnormal result of this test in the recent history of the patient and there is no related clinical sign) or the result of a temporary and reversible medical condition, once that condition is resolved.]
  • Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment) at Visit 1.
  • Previous treatment with nintedanib.
  • Other investigational therapy received within 1 month or 5 half-lives (whichever is shorter but ≥1 week) prior to Visit 2.
  • Significant pulmonary arterial hypertension (PAH) defined by any of the following:

    • Previous clinical or echocardiographic evidence of significant right heart failure
    • History of right heart catheterization showing a cardiac index ≤2 l/min/m²
    • PAH requiring parenteral therapy with epoprostenol/treprostinil
  • In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
  • Cardiovascular diseases, any of the following:

    • Severe hypertension, uncontrolled under treatment, within 6 months of Visit 1. Uncontrolled hypertension is defined as

      • In children 6 to ≤12 years old: ≥95th percentile + 12 mm Hg or ≥140/90 mm Hg (whichever is lower) (systolic or diastolic blood pressure equal to or greater than the calculated target value)
      • In adolescents 13 to 17 years old: systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg
    • Myocardial infarction within 6 months of Visit 1
    • Unstable cardiac angina within 6 months of Visit 1
  • Bleeding risk, any of the following:

    • Known genetic predisposition to bleeding
    • Patients who require

      • Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin)
      • High dose antiplatelet therapy [Note: Prophylactic low dose heparin or heparin flush as needed for maintenance of an indwelling intravenous device (e.g. enoxaparin 4000 I.U. s.c. per day), as well as prophylactic use of antiplatelet therapy (e.g. acetyl salicylic acid up to 325 mg/day, or clopidogrel at 75 mg/day, or equivalent doses of other antiplatelet therapy) are not prohibited.]
    • History of haemorrhagic central nervous system (CNS) event within 12 months of Visit 1
    • Any of the following within 3 months of Visit 1:

      • Haemoptysis or haematuria
      • Active gastro-intestinal (GI) bleeding or GI - ulcers
      • Major injury or surgery (investigator's judgment)
    • Any of the following coagulation parameters at Visit 1:

      • International normalized ratio (INR) >2
      • Prolongation of prothrombin time (PT) by >1.5 x ULN
      • Prolongation of activated partial thromboplastin time (aPTT) by >1.5 x ULN
  • History of thrombotic event (including stroke and transient ischemic attack) within 12 months of Visit 1.
  • Known hypersensitivity to the trial medication or its components (i.e. soya lecithin).
  • Patients with documented allergy to peanut or soya.
  • Other disease that may interfere with testing procedures or in the judgment of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial.
  • Life expectancy for any concomitant disease other than Interstitial Lung Disease (ILD)<2.5 years (investigator assessment).
  • Female patients who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • Patients not able or willing to adhere to trial procedures, including intake of study medication.
  • Patients with any diagnosed growth disorder such as growth hormone deficiency or any genetic disorder that is associated with short stature (e.g. Turner Syndrome, Noonan Syndrome, Russell-Silver Syndrome) and/or treatment with growth hormone therapy within 6 months before Visit 2. Patients with short stature considered by the investigator to be due to glucocorticoid therapy may be included.
  • Patients <13.5 kg of weight at Visit 1 (same threshold to be used for male and female patients).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04093024

Show Show 43 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT04093024    
Other Study ID Numbers: 1199-0337
2018-004530-14 ( EudraCT Number )
First Posted: September 17, 2019    Key Record Dates
Last Update Posted: June 22, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description:

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:

  1. studies in products where Boehringer Ingelheim is not the license holder;
  2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
  3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).

For more details refer to: https://www.mystudywindow.com/msw/datasharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action